Get the latest Science News and Discoveries

Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma


None

Get the Android app

Or read this on ScienceDaily

Read more on:

Photo of Immunotherapy

Immunotherapy

Photo of III

III

Related news:

News photo

Cancer-seeking molecular delivery system could boost immunotherapy drug

News photo

Cancer biomarker data is not diverse, with implications for immunotherapy patients from underrepresented groups

News photo

Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy